Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $227M (up 18.0% year over year) with net income of $21M.
Q3 2026 key financials · XBRL
- Revenue
- $227M
- +18.0% YoY · +3.5% QoQ
- Net income
- $21M
- +146.4% YoY · +135.8% QoQ
- Operating margin
- 9.3%
- EPS (diluted)
- $0.36
- +145.0% YoY · +135.6% QoQ
Source: XBRL data from the SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q3 2026 10-Q on SEC EDGAR. USD.
SUPERNUS PHARMACEUTICALS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $226.8M, up 18% YoY from $192.1M
- Operating margin not disclosed; net loss $39.8M for nine months vs $34.4M YoY
- Best performer: ONAPGO sales $17.1M, up 151% YoY; worst: APOKYN sales $6.5M, down 38%
- Cash and securities $359.5M at September 30; operating cash flow $68.3M for nine months vs $27.5M YoY
- Outlook: cash sufficient beyond twelve months; headwinds from generic erosion, payor pressure, and potential merger-related cash reduction
Risk Factors
- Pending Indivior merger: completion conditions may fail or face delays, potentially causing material business disruption
- Merger litigation: two New York complaints filed September 16-17, 2026, seeking injunctions and damages
- Financing risk: Indivior’s $650 million Term Loan Facility may be unavailable, forcing an Alternative Dividend
- Combined-company leverage: existing $500 million 0.625% Convertible Senior Notes due 2031 plus merger-related debt
- Fixed exchange ratio: Supernus shareholders receive 1.5401 Indivior shares regardless of stock-price changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SUPERNUS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.